Item 1.01 Entry into a Material Definitive Agreement.
On
The Company intends to use the net proceeds from the offering, along with the proceeds from certain debt financing transactions, to finance its previously announced acquisition of the Masterflex bioprocessing business and related assets of Antylia Scientific. To the extent the acquisition is not consummated, the Company anticipates using the net proceeds of the offering for general corporate purposes.
The description of the Underwriting Agreement is qualified in its entirety by the terms of such agreement, which is incorporated herein by reference and attached to this report as Exhibit 1.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit Number Description 1.1 Underwriting Agreement, datedSeptember 13, 2021 , by and amongAvantor, Inc. andGoldman Sachs & Co. LLC ,Citigroup Global Markets Inc. andBofA Securities, Inc. , as representatives of the several underwriters named therein. 5.1 Opinion ofSimpson Thacher & Bartlett LLP 23.1 Consent ofSimpson Thacher & Bartlett LLP (including in Exhibit 5.1) 104 Cover Page Interactive Data File (formatted as Inline XBRL) 2
--------------------------------------------------------------------------------
© Edgar Online, source